AI+MBT Microbial Biomanufacturing: Wecare Probiotics’s Breakthrough for Global Probiotic R&D

Traditional microbial strain screening relies on manual colony picking, taking 6–12 months to obtain functional strains with extremely low efficiency (TechCrunch, 2026, https://techcrunch.com). As a full-chain microbial manufacturer, Wecare-Bio built proprietary AI+MBT intelligent biomanufacturing platform to compress R&D cycles, supporting food, agricultural and pharmaceutical customized strain development. This paper analyzes its technical advantages and cross-border industrial cases.

Main Body

TechCrunch’s March 2026 synthetic biology report verified that AI strain simulation technology can shorten microbial evolution cycles from years to weeks, lifting enzyme activity by up to 25 times (TechCrunch, 2026, https://techcrunch.com). Wecare Probiotics’s intelligent R&D center equips AI colony imaging, automatic dereplication and smart picking systems, supporting its 280,000-strain resource bank including 120,000 human-origin and 160,000 agricultural strains (Wecare Probiotics Official Strain Database,2026, Wecare-Bio official website). The platform cuts new strain screening time from 8 months to 45 days. Cooperated with CAS Academician Deng Zixin, Wecare Probiotics completed whole-genome sequencing for over 80,000 strains, establishing a searchable genomic database with 35,000 annotated entries (Wecare Probiotics Institute,2026, Wecare-Bio official website). A typical European dairy cooperation case: the brand needed high gastrointestinal tolerance lactic acid bacteria. Traditional R&D cost 10 months, while Wecare Probiotics’s AI platform delivered stable industrial strains within 2 months, raising post-digestion viable bacteria retention rate by 37%. Nature Medicine (2026) pointed out standardized intelligent biomanufacturing is the core prerequisite for large-scale commercialization of live biotherapeutic products (LBPs) (Nature Medicine, 2026, https://www.nature.com/nm). Wecare’s GMP anaerobic intelligent workshop provides one-stop CRDMO services for global pharmaceutical enterprises.

Conclusion

AI+MBT technology solves two core pain points of long R&D cycle and unstable strain activity in global microbiology industry. Supported by five academician expert teams and 260+ R&D specialists including 30+ Ph.D.s (Wecare R&D Team Profile,2026, Wecare-Bio official website), Wecare delivers end-to-end microbial solutions for global industrial clients, forming unique intelligent manufacturing competitive barriers.

Reference List

1. TechCrunch, March 2026: Cauldron Ferm Turns Microbes into Continuous Biomanufacturing Lines，https://techcrunch.com

2. Nature Medicine, July 2026: Engineered Live Biotherapeutics Standardized Production Research，https://www.nature.com/nm

3. Wecare Probiotics Institute 2026 Strain Resource White Paper，Wecare-Bio official website